These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 37568798)

  • 1. Clinical Significance of Nectins in HCC and Other Solid Malignant Tumors: Implications for Prognosis and New Treatment Opportunities-A Systematic Review.
    Klekowski J; Zielińska D; Hofman A; Zajdel N; Gajdzis P; Chabowski M
    Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of Nectin-4 in Chromophobe Renal Cell Carcinoma in a Multicenter Cohort: Early Prognostic and Therapeutic Considerations.
    Mikuteit M; Zschäbitz S; Autenrieth M; Weichert W; Hartmann A; Steffens S; Erlmeier F
    Oncology; 2024; 102(6):503-509. PubMed ID: 38043528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma.
    Wong JL; Rosenberg JE
    Expert Opin Biol Ther; 2021 Jul; 21(7):863-873. PubMed ID: 34030536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High expression of nectin-1 indicates a poor prognosis and promotes metastasis in hepatocellular carcinoma.
    Wang X; Xing Z; Chen H; Yang H; Wang Q; Xing T
    Front Oncol; 2022; 12():953529. PubMed ID: 36059705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers.
    Zhou W; Fang P; Yu D; Ren H; You M; Yin L; Mei F; Zhu H; Wang Z; Xu H; Cao Y; Sun X; Xu X; Bi J; Wang J; Ma L; Wang X; Chen L; Zhang Y; Cen X; Zhu X; Lou L; Liu D; Tan X; Yang J; Meng T; Shen J
    Mol Cancer Ther; 2023 Aug; 22(8):913-925. PubMed ID: 37196158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.
    Lacouture ME; Patel AB; Rosenberg JE; O'Donnell PH
    Oncologist; 2022 Mar; 27(3):e223-e232. PubMed ID: 35274723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma].
    Klümper N; Eckstein M; Kunath F; Heidegger I; Becker C; Rausch S;
    Urologie; 2023 Nov; 62(11):1193-1199. PubMed ID: 37658236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors.
    Rigby M; Bennett G; Chen L; Mudd GE; Harrison H; Beswick PJ; Van Rietschoten K; Watcham SM; Scott HS; Brown AN; Park PU; Campbell C; Haines E; Lahdenranta J; Skynner MJ; Jeffrey P; Keen N; Lee K
    Mol Cancer Ther; 2022 Dec; 21(12):1747-1756. PubMed ID: 36112771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nectin-4 is widely expressed in head and neck squamous cell carcinoma.
    Sanders C; Lau JF; Dietrich D; Strieth S; Brossart P; Kristiansen G
    Oncotarget; 2022 Oct; 13():1166-1173. PubMed ID: 36268557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
    Klümper N; Ralser DJ; Ellinger J; Roghmann F; Albrecht J; Below E; Alajati A; Sikic D; Breyer J; Bolenz C; Zengerling F; Erben P; Schwamborn K; Wirtz RM; Horn T; Nagy D; Toma M; Kristiansen G; Büttner T; Hahn O; Grünwald V; Darr C; Erne E; Rausch S; Bedke J; Schlack K; Abbas M; Zschäbitz S; Schwab C; Mustea A; Adam P; Manseck A; Wullich B; Ritter M; Hartmann A; Gschwend J; Weichert W; Erlmeier F; Hölzel M; Eckstein M
    Clin Cancer Res; 2023 Apr; 29(8):1496-1505. PubMed ID: 36534531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nectin-4: a Novel Therapeutic Target for Skin Cancers.
    Hashimoto H; Tanaka Y; Murata M; Ito T
    Curr Treat Options Oncol; 2022 Apr; 23(4):578-593. PubMed ID: 35312963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Potential of Nectin Expressions in Colorectal Cancer: An Exploratory Study.
    Kobecki J; Gajdzis P; Mazur G; Chabowski M
    Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic prospects of nectin-4 in cancer: applications and value.
    Li K; Zhou Y; Zang M; Jin X; Li X
    Front Oncol; 2024; 14():1354543. PubMed ID: 38606099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enfortumab vedotin in the treatment of urothelial cancers and beyond.
    Wong RL; Yu EY
    Future Oncol; 2022 Sep; 18(27):3067-3084. PubMed ID: 36004667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor expression of Nectin-1-4 and its clinical implication in muscle invasive bladder cancer: An intra-patient variability of Nectin-4 expression.
    Miyake M; Miyamoto T; Shimizu T; Ohnishi S; Fujii T; Nishimura N; Oda Y; Morizawa Y; Hori S; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Fujimoto K
    Pathol Res Pract; 2022 Sep; 237():154072. PubMed ID: 35986963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intertriginous erythema associated with enfortumab vedotin, a nectin-4-targeting antibody-drug conjugate, in a case with metastatic urothelial cancer: Immunohistochemical evidence for molecular-targeted eruption.
    Hasegawa T; Oyama N; Kasamatsu H; Chino T; Taga M; Hasegawa M
    J Dermatol; 2022 Dec; 49(12):e453-e454. PubMed ID: 36052729
    [No Abstract]   [Full Text] [Related]  

  • 17. Nectin cell adhesion molecule-4 (NECTIN-4): A potential target for cancer therapy.
    Chatterjee S; Sinha S; Kundu CN
    Eur J Pharmacol; 2021 Nov; 911():174516. PubMed ID: 34547246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?
    Filippi L; Schillaci O
    Expert Rev Anticancer Ther; 2024; 24(1-2):1-4. PubMed ID: 37994866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma.
    Duan X; Xia L; Zhang Z; Ren Y; Pomper MG; Rowe SP; Li X; Li N; Zhang N; Zhu H; Yang Z; Sheng X; Yang X
    Clin Cancer Res; 2023 Sep; 29(17):3395-3407. PubMed ID: 37093191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Anti-Nectin 4: A Promising Tumor Cells Target. A Systematic Review.
    Bouleftour W; Guillot A; Magne N
    Mol Cancer Ther; 2022 Apr; 21(4):493-501. PubMed ID: 35131876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.